Association between the lipoprotein-associated phospholipase A2 activity and the progression of subclinical atherosclerosis

Journal of Atherosclerosis and Thrombosis

Volumn 21, Issue 6, 2014, Pages 532-542

  Liu, Jing ^a   Wang, Wei ^a   Qi, Yue ^a   Yong, Qiang ^a   Zhou, Guanghua ^b   Wang, Miao ^a   Sun, Jiayi ^a   Liu, Jun ^a   Jia, Zhangrong ^a   Zhao, Dong ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b Ministry of Education Beijing   (China)

Author keywords

Atherosclerosis; Cohort study; Lipoprotein associated phospholipase A2

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ADULT; AGE; AGED; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; ECHOGRAPHY; ENZYME ACTIVITY; FEMALE; FRAMINGHAM RISK SCORE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; QUESTIONNAIRE; RISK FACTOR; SMOKING; ATHEROSCLEROTIC PLAQUE; CHINA; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; REGRESSION ANALYSIS;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CAROTID INTIMA-MEDIA THICKNESS; CHINA; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; REGRESSION ANALYSIS; RISK FACTORS;

EID: 84903208477     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.20941     Document Type: Article

References (30)

1. Stafforini DM, Prescott SM, McIntyre TM: Human plasma platelet-activating factor acetylhydrolase. Purification and properties. J Biol Chem, 1987; 262: 4223-4230
2. MacPhee CH, Moores KE, Boyd HF, Dhanak D, Ife RJ, Leach CA, Leake DS, Milliner KJ, Patterson RA, Suckling KE, Tew DG, Hickey DM: Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J, 1999; 338: 479-487
3. Häkkinen T, Luoma JS, Hiltunen MO, Macphee CH, Milliner KJ, Patel L, Rice SQ, Tew DG, Karkola K, Ylä-Herttuala S: Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol, 1999; 19: 2909-2917
4. Lp-PLA2 Studies Collaboration, Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, Ballantyne C, Cannon CP, Criqui M, Cushman M, Hofman A, Packard C, Thompson SG, Collins R, Danesh J: Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet, 2010; 375: 1536-1544
5. Epps KC, Wilensky RL: Lp-PLA2-a novel risk factor for high-risk coronary and carotid artery disease. J Intern Med, 2011; 269: 94-106
6. Packard CJ: Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target. Curr Opin Cardiol, 2009; 24: 358-363
7. Iribarren C, Gross MD, Darbinian JA, Jacobs DR Jr, Sidney S, Loria CM: Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study. Arterioscler Thromb Vasc Biol, 2005; 25: 216-221
8. Kardys I, Oei HH, van der Meer IM, Hofman A, Breteler MM, Witteman JC: Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam Study. Arterioscler Thromb Vasc Biol, 2006; 26: 631-636
9. Kardys I, Oei HH, Hofman A, Oudkerk M, Witteman JC: Lipoprotein-associated phospholipase A2 and coronary calcification. The Rotterdam Coronary Calcification Study. Atherosclerosis, 2007; 191: 377-383
10. Brilakis ES, Khera A, Saeed B, Banerjee S, McGuire DK, Murphy SA, de Lemos JA: Association of lipoproteinassociated phospholipase A2 mass and activity with coronary and aortic atherosclerosis: findings from the Dallas Heart Study. Clin Chem, 2008; 54: 1975-1981
11. Saremi A, Moritz TE, Anderson RJ, Abraira C, Duckworth WC, Reaven PD: Rates and determinants of coronary and abdominal aortic artery calcium progression in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care, 2010; 33: 2642-2647
12. Kinney GL, Snell-Bergeon JK, Maahs DM, Eckel RH, Ehrlich J, Rewers M, Hokanson JE: Lipoprotein-associated phospholipase A2 activity predicts progression of subclinical coronary atherosclerosis. Diabetes Technol Ther, 2011; 13: 381-387
13. Liu J, Grundy SM, Wang W, Smith SC Jr, Vega GL, Wu Z, Zeng Z, Wang W, Zhao D: Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome. Am Heart J, 2007; 153: 552-558
14. WHO MONICA Project. MONICA Manual. http://www. ktl.fi/publications/monica/manual/index.htm. Accessed July 17, 2013
15. Sander D, Schulze-Horn C, Bickel H, Gnahn H, Bartels E, Conrad B: Combined effects of hemoglobin A1c and C-reactive protein on the progression of subclinical carotid atherosclerosis: the INVADE study. Stroke, 2006; 37: 351-357
16. Van Der Meer IM, De Maat MP, Hak AE, Kiliaan AJ, Del Sol AI, Van Der Kuip DA, Nijhuis RL, Hofman A, Witteman JC: C-reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree: the Rotterdam Study. Stroke, 2002; 33: 2750-2755
17. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation, 1998; 97: 1837-1847
18. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA, 2003; 289: 2560-2572
19. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care, 2003; 26 Suppl 1: S5-20
20. Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, Rumley A, Lowe GD: Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med, 2000; 343: 1148-1155
21. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, Sharrett AR: Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation, 2004; 109: 837-842
22. Elkind MS, Tai W, Coates K, Paik MC, Sacco RL: Highsensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med, 2006; 166: 2073-2080
23. Musialek P, Tracz W, Tekieli L, Pieniazek P, Kablak-Ziembicka A, Przewlocki T, Stepien E, Kapusta P, Motyl R, Stepniewski J, Undas A, Podolec P: Multimarker approach in discriminating patients with symptomatic and asymptomatic atherosclerotic carotid artery stenosis. J Clin Neurol, 2013; 9: 165-175
24. Constantinides A, van Pelt LJ, van Leeuwen JJ, de Vries R, Tio RA, van der Horst IC, Sluiter WJ, Dullaart RP: Carotid intima media thickness is associated with plasma lipoprotein-associated phospholipase A2 mass in nondiabetic subjects but not in patients with type 2 diabetes. Eur J Clin Invest, 2011; 41: 820-827
25. Gong HP, Du YM, Zhong LN, Dong ZQ, Wang X, Mao YJ, Lu QH: Plasma lipoprotein-associated phospholipase A2 in patients with metabolic syndrome and carotid atherosclerosis. Lipids Health Dis, 2011; 10: 13
26. Saremi A, Anderson RJ, Luo P, Moritz TE, Schwenke DC, Allison M, Reaven PD; VADT. Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT). Atherosclerosis, 2009; 203: 610-614
27. Miyaura S, Maki N, Byrd W, Johnston JM: The hormonal regulation of platelet-activating factor acetylhydrolase activity in plasma. Lipids, 1991; 26: 1015-1020
28. Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, Virmani R: Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol, 2006; 26: 2523-2529
29. Ridker PM, MacFadyen JG, Wolfert RL, Koenig W: Relationship of lipoprotein-associated phospholipase A2 mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial. Clin Chem, 2012; 58: 877-886
30. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, Gupta R, Kelishadi R, Iqbal R, Avezum A, Kruger A, Kutty R, Lanas F, Lisheng L, Wei L, Lopez-Jaramillo P, Oguz A, Rahman O, Swidan H, Yusoff K, Zatonski W, Rosengren A, Teo KK; Prospective Urban Rural Epidemiology (PURE) Study Investigators: Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and lowincome countries (the PURE Study): a prospective epidemiological survey. Lancet, 2011; 378: 1231-1243